A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

Non-alcoholic Fatty Liver Disease Clinical Trial

— EMMINENCE  

Official title:

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02784444
• Other study ID #: MSDC-0602K-C009NASH
• Status: Completed
• Phase: Phase 2
• Start date: September 14, 2016
• Est. completion date: June 2019

Study information

• Verified date: August 2020
• Source: Cirius Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis.

Description:

This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis. Visits to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12 months, with one 2- week follow-up visit.

Safety will be assessed by monitoring of vital signs, 12 lead electrocardiogram (ECG), physical examinations, safety labs, and adverse events (AEs).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 392
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Selected Inclusion Criteria:

• Adult subjects 18 years of age or greater

• Histological evidence of NASH, based on biopsy, with a NAS (NASH CRN scoring) = 4 with a score of at least 1 in each component of NAS.

• Histological evidence of liver fibrosis defined as NASH CRN System fibrosis score F1 to F3.

• Subjects with type 2 diabetes mellitus (DM) must be under stable and reasonable control.

• Male and female subjects who are taking Vitamin E should be on a stable dose of Vitamin E (if = 400 IU) for a period of at least 3 months prior to randomization.

• Females should be either postmenopausal (at least 12 months since last menses) or surgically sterilized (bilateral tubal ligation or hysterectomy). Males with female partners of child-bearing potential must agree to use adequate contraceptive methods (including a condom, plus one other form of contraception) if engaging in sexual intercourse.

• Willing and able to sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.

Selected Exclusion Criteria:

• Known history of HIV.

• Prior liver transplantation.

• Other well-documented causes of active chronic liver disease.

• History of cirrhosis and/or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding.

• History of alcohol abuse or drug abuse within 6 months of Screening.

• Type 1 diabetes mellitus.

• Current or history of recent (= 6 months) use of ursodeoxycholic acid.

• Use of concomitant medications with a known significant metabolism by CYP2C8 or CPY2C9.

• History of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 6 months prior to randomization.

• History of heart failure (including CHF) or previous cardiovascular event (myocardial infarct, by-pass surgery, or PTCA) within the past 6 months prior to randomization.

• Blood pressure greater than 160/100 mmHg.

• Participation in an investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to study drug administration.

• Malignancy, including leukemia and lymphoma (excluding basal cell and squamous skin cell cancers and localized prostrate cancer) treated within the last 2 years.

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• NASH - Nonalcoholic Steatohepatitis
• Non-alcoholic Fatty Liver Disease
• Non-alcoholic Steatohepatitis

Intervention

Drug:
• MSDC-0602K
MSDC-0602K capsules
• Placebo
Placebo capsules

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Cirius Therapeutics, Inc.	Chiltern International Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Hepatic Histological Improvement in NAS	A decrease of at least 2 points in NAS at 12 months.; At least a 1 point reduction in either ballooning or inflammation from baseline to 12 months.; no increase in CRN fibrosis score (i.e., an increase of 1 stage or more) from baseline to 12 months.	12 months (360 days)
Secondary	Number of Subjects With Resolution of NASH With no Worsening of Fibrosis at 12 Months.	CRN ballooning score of 0 at 12-months; CRN inflammation score of 0 or 1 at 12-months; No increase in CRN fibrosis score from baseline to 12-months	12 months (360 days)
Secondary	Number of Subjects With Improvement of Fibrosis (CRN Staging Score) by at Least 1 Stage With no Worsening of NASH at 12 Months.	Decrease in fibrosis CRN staging score of >= 1 full stage from baseline to 12 months; No increase in ballooning CRN score from baseline to 12 months; No increase in inflammation CRN score from baseline to 12-months	12 months (360 days)
Secondary	Mean Change From Baseline in NAFLD Activity Score (NAS)	NAS is the sum of the scores of steatosis, inflammation, and ballooning. It has a range of 0 to 8 with higher scores indicating worse disease severity.	12 months (360 days)
Secondary	Mean Change From Baseline in CRN Steatosis Score	Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.	12 months (360 days)
Secondary	Mean Change From Baseline in CRN Inflammation Score	Inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe inflammation.	12 months (360 days)
Secondary	Mean Change From Baseline in CRN Ballooning Score	Hepatocellular ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe hepatocellular ballooning.	12 months (360 days)
Secondary	Mean Change From Baseline in CRN Fibrosis Staging Score	Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.	12 months (360 days)